BioInformant

Your Global Leader in Stem Cell Market Research

Home » Stem Cells » MSCs » Page 57

Mesenchymal Stem Cells (MSCs)

Mesenchymal stem cells (MSCs) are a well-characterized population of adult stem cells that can differentiate into a variety of cell types (chondrocytes, osteoblasts, adipocytes, myocytes, and more).

(My Story) President of a Stem Cell Market Research Firm and a Stem Cell Patient

By 1 Comment

For the past 15 years, I have studied stem cells, including technology and research advances, as well as market trends. I have been fascinated with them for most of my adult life, founding BioInformant as the first and only market research firm to specialize in the stem cell industry.

As a result of this decision, I have had the honor of serving thousands clients from across the stem cell industry and been interviewed by the Wall Street Journal, Los Angeles Business Journal, Xconomy, and Vogue Magazine.

However, it was only recently that I experienced the power of stem cells to impact my own life and health.

[Read more…]

“Cord Blood” Reaches Nearly $40 Per Click in the U.S. and More Than $20 Per Click Worldwide

By 1 Comment

Because Google controls over 70% of online searches, it is an incredible resource for analyzing online search behavior. Recently, the search term “Cord Blood” became one of the 20 most expensive keywords on Google Adwords,[1] an incredible finding given the variety and total volume of searches that occur through Google.

Individuals or companies who buy the exact search phrase “Cord Blood” through Google AdWords now pay $38.38[2] to win search traffic for this phrase within the United States. [Read more…]

What Percentage of U.S. Parents Store Cord Blood Publicly and Privately?

By Leave a Comment

The cord blood banking industry has grown increasingly complex over the past few years. While rates of growth within the industry were robust during the early 2000’s, it is no longer the rapid growth market that it used to be. There is now increased market competition, tighter regulatory standards, more substantial government oversight, and increased public scrutiny given toward cord blood industry practices.
[Read more…]

BioInformant's World-Class Clients